-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $1.38
RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below 200 Day Moving Average of $1.38
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating)'s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.38 and traded as low as $0.85. RedHill Biopharma shares last traded at $0.89, with a volume of 393,337 shares.
RedHill Biopharma Price Performance
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The stock has a market capitalization of $46.82 million, a P/E ratio of -0.47 and a beta of 1.80. The company's 50 day simple moving average is $0.94 and its two-hundred day simple moving average is $1.38.
Get RedHill Biopharma alerts:RedHill Biopharma (NASDAQ:RDHL – Get Rating) last released its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The business had revenue of $18.24 million for the quarter. During the same period last year, the company earned ($0.53) earnings per share. As a group, equities analysts expect that RedHill Biopharma Ltd. will post -0.83 EPS for the current fiscal year.
Institutional Investors Weigh In On RedHill Biopharma
A number of hedge funds and other institutional investors have recently made changes to their positions in RDHL. Disciplined Growth Investors Inc. MN increased its stake in RedHill Biopharma by 0.7% in the 1st quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company's stock valued at $4,914,000 after buying an additional 14,413 shares during the last quarter. ARK Investment Management LLC grew its position in shares of RedHill Biopharma by 21.3% in the 2nd quarter. ARK Investment Management LLC now owns 1,045,023 shares of the biotechnology company's stock valued at $1,170,000 after acquiring an additional 183,225 shares during the period. Millennium Management LLC bought a new position in shares of RedHill Biopharma in the 2nd quarter valued at about $324,000. Gagnon Securities LLC boosted its holdings in shares of RedHill Biopharma by 15.4% during the 1st quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after buying an additional 49,023 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of RedHill Biopharma by 18.6% during the 1st quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company's stock worth $901,000 after buying an additional 56,178 shares during the period. 7.74% of the stock is currently owned by institutional investors and hedge funds.RedHill Biopharma Company Profile
(Get Rating)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Further Reading
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating)'s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.38 and traded as low as $0.85. RedHill Biopharma shares last traded at $0.89, with a volume of 393,337 shares.
红山生物医药股份有限公司(纳斯达克代码：RDHL-GET评级)的股价在周五的交易中跌破200日移动均线，200日移动均线为1.38美元，最低交易价格为0.85美元。红山生物医药的股票最新报0.89美元，成交量为393,337股。
RedHill Biopharma Price Performance
红山生物医药的价格表现
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The stock has a market capitalization of $46.82 million, a P/E ratio of -0.47 and a beta of 1.80. The company's 50 day simple moving average is $0.94 and its two-hundred day simple moving average is $1.38.
该公司的债务权益比为9.42，流动比率为0.98，速动比率为0.79。该股市值为4,682万美元，市盈率为-0.47，贝塔系数为1.80。该公司的50日简单移动均线切入位为0.94美元，200日简单移动均线切入位为1.38美元。
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last released its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The business had revenue of $18.24 million for the quarter. During the same period last year, the company earned ($0.53) earnings per share. As a group, equities analysts expect that RedHill Biopharma Ltd. will post -0.83 EPS for the current fiscal year.
红山生物科技(纳斯达克代码：RDHL-GET Rating)最近一次发布季度收益报告是在6月23日(星期四)。这家生物技术公司公布了本季度每股收益(0.30美元)，比普遍预期的(0.40美元)高出0.10美元。红山生物医药的净利润率为负110.31%，净资产回报率为负822.29%。该业务本季度的收入为1824万美元。去年同期，该公司每股收益为0.53美元。股票分析师预计，作为一个整体，红山生物科技有限公司本财年每股收益将达到0.83欧元。
Institutional Investors Weigh In On RedHill Biopharma
机构投资者买入红山生物医药
RedHill Biopharma Company Profile
红山生物医药公司简介
(Get Rating)
(获取评级)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
红山生物制药有限公司是一家专业的生物制药公司，主要专注于胃肠道和传染病。该公司推广胃肠药物，包括用于治疗患有慢性非癌症疼痛的成人阿片类药物引起的便秘的Movantik；用于治疗成人幽门螺杆菌感染的Talicia；以及用于治疗成人旅行者腹泻的Aemcolo。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于RedHill Biophma(RDHL)的研究报告
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏，这些股票可能表现优异
- DocuSign是否即将发生重大逆转？
- 石油和天然气股票：投资可再生能源的安全途径
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《红山生物报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对RedHill Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧